The company operates as a Contract Research Organisation by providing preclinical and clinical research services to the global pharma industry.
It said its recent move to the newly built Pioneer Group life sciences facilities in Cherrywood in Dublin has initiated a"transformative" phase of growth for the company, opening doors to a new industry network. The company said it is currently hiring for preclinical and clinical neuroscience positions in the psychedelic, psychiatric and rare neurodevelopmental research space.
"This raise of €500,000 in investment is an important milestone allowing us to expand our patient-centric and translational neuroscience research platforms," said Dr. Massimiliano Bianchi, CEO of Ulysses Neuroscience. "With a portfolio of globally based pharma clients and an annual revenue of over €1 million, we have been able to breakthrough the CRO market and are helping a range of industries to bring their new therapies into clinical trials and subsequently onto the market," he added.